Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease

Inclusion Criteria: * Diagnosed with ileal, ileo-colonic, or colonic Crohn's disease for a minimum of 6 months prior to initiating study drug * Moderately to severely active Crohn's disease, as defined by a CDAI score \>250 and \< 450 at baseline * Evidence of active inflammation Exclusion Criteria: * Short bowel syndrome * Stricture with obstructive symptoms within 3 months * Bowel surgery within 3 months * Ileostomy and/or colostomy * Any gastric or intestinal pouch * Ulcerative colitis * Evidence of an infected abscess * Bowel perforation or evidence of noninflammatory obstruction during the 6 months * Stool positive for C. Difficile toxin at screening * Presence of active infection requiring treatment * Serious infection within 8 weeks * Significant concurrent medical conditions * Pregnant or breast feeding * Significant Laboratory abnormalities * Any anti-tumor necrosis factor (TNF) agent within 2 months * Steroid enemas within 2 weeks * Tysabri (natalizumab) within 1 year * Biologic agents (eg, ustekinumab), experimental procedures, or live vaccines within 3 months * Cyclosporine, mycophenolate mofetil, sirolimus (rapamycin),thalidomide or tacrolimus within 2 months